Compile Data Set for Download or QSAR
maximum 50k data
Found 210
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493100(1-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihy...)
Affinity DataIC50:  0.300nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493065(2-((1r,4r)-4-(2-(2-Oxo-2-(4-(trifluoromethyl)piper...)
Affinity DataIC50:  0.400nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493101(2-((1r,4r)-4-(2-(Thiazol-4-ylmethyl)imidazo[4,5-d]...)
Affinity DataIC50:  0.600nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493067(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.700nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493066(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.900nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493281(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  1.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387823(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  1.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493070(2-((1r,4r)-4-(2-(Oxazol-4-yl)imidazo[4,5-d]pyrrolo...)
Affinity DataIC50:  1.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493269(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  1.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493156((EZ)—N-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl...)
Affinity DataIC50:  1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493076((E)-N-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-...)
Affinity DataIC50:  1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493071(2-((1r,4r)-4-(2-(2-(4-Hydroxypiperidin-1-yl)-2-oxo...)
Affinity DataIC50:  1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387828(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  1.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(2-((1r,4r)-4-(2-(1H-Imidazol-4-yl)imidazo[4,5-d]py...)
Affinity DataIC50:  1.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493068(2-((1r,4r)-4-(2-(1H-1,2,4-Triazol-3-yl)imidazo[4,5...)
Affinity DataIC50:  1.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493090(N-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihy...)
Affinity DataIC50:  1.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493080(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  1.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493096(N-((1H-imidazol-2-yl)methyl)-2-(1-((1r,4r)-4-(cyan...)
Affinity DataIC50:  2.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(N-(2-Cyanoethyl)-2-(1-((1r,4r)-4-(cyanomethyl)cycl...)
Affinity DataIC50:  2.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493150(2-((1r,4r)-4-(2-(2-Oxo-2-(piperidin-1-yl)ethyl)imi...)
Affinity DataIC50:  2.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493146(N-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihy...)
Affinity DataIC50:  2.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527404(CHEMBL4514898 | US10981911, Example 62)
Affinity DataIC50:  2.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527405(CHEMBL4456630 | US10981911, Example 26)
Affinity DataIC50:  2.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493073(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  2.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493126(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  2.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493092(N-((3R,5R)-Adamantan-1-yl)-2-(1-((1r,4r)-4-(cyanom...)
Affinity DataIC50:  2.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493221((3R,5R,7R)—N-((1-((1r,4r)-4-(Cyanomethyl)cycl...)
Affinity DataIC50:  2.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493077((Z)—N-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-...)
Affinity DataIC50:  2.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387825(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  3.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493131(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527409(CHEMBL4447497 | US10981911, Example 58)
Affinity DataIC50:  3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493072(2-Cyano-N-((1-((1r,4r)-4-(cyanomethyl)cyclohexyl)-...)
Affinity DataIC50:  3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493084(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493120(2-((1r,4r)-4-(2-(1H-Pyrazol-3-yl)imidazo[4,5-d]pyr...)
Affinity DataIC50:  3.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527410(CHEMBL4439418 | US10981911, Example 57)
Affinity DataIC50:  3.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493088(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  3.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493083(N-(4-Cyanobicyclo[2.2.1]heptan-1-yl)-2-(1-((1r,4r)...)
Affinity DataIC50:  3.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493081(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  3.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493075(2-((1r,4r)-4-(2-(2H-1,2,3-Triazol-4-yl)imidazo[4,5...)
Affinity DataIC50:  3.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493091(2-((1r,4r)-4-(2-(4-Chloro-1H-pyrazol-3-yl)imidazo[...)
Affinity DataIC50:  3.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493089(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  3.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527407(CHEMBL4582390 | US10981911, Example 33)
Affinity DataIC50:  3.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493127(2-((1r,4r)-4-(2-(2-(1,1-Dioxidothiomorpholino)-2-o...)
Affinity DataIC50:  3.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387824(N-(2-Cyano-2-methylpropyl)-2-(1-((1r,4r)-4-(cyanom...)
Affinity DataIC50:  4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493074(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493140(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-N-((3-hydrox...)
Affinity DataIC50:  4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387822(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493114(4-(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-di...)
Affinity DataIC50:  4.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493109(2-((1r,4r)-4-(2-(2-Oxo-2-(pyrrolidin-1-yl)ethyl)im...)
Affinity DataIC50:  4.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493097(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  4.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 210 total ) | Next | Last >>
Jump to: